Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 105

1.

The relationship between proton pump inhibitor use and longitudinal change in bone mineral density: a population-based study [corrected] from the Canadian Multicentre Osteoporosis Study (CaMos).

Targownik LE, Leslie WD, Davison KS, Goltzman D, Jamal SA, Kreiger N, Josse RG, Kaiser SM, Kovacs CS, Prior JC, Zhou W; CaMos Research Group.

Am J Gastroenterol. 2012 Sep;107(9):1361-9. doi: 10.1038/ajg.2012.200. Epub 2012 Jul 10. Erratum in: Am J Gastroenterol. 2013 Jan;108(1):157.

2.

Proton-pump inhibitor use is not associated with osteoporosis or accelerated bone mineral density loss.

Targownik LE, Lix LM, Leung S, Leslie WD.

Gastroenterology. 2010 Mar;138(3):896-904. doi: 10.1053/j.gastro.2009.11.014. Epub 2009 Nov 18.

PMID:
19931262
3.

Proton pump inhibitors use and change in bone mineral density.

Arj A, Razavi Zade M, Yavari M, Akbari H, Zamani B, Asemi Z.

Int J Rheum Dis. 2016 Sep;19(9):864-8. doi: 10.1111/1756-185X.12866. Epub 2016 May 31.

PMID:
27242025
4.

Esomeprazole use is independently associated with significant reduction of BMD: 1-year prospective comparative safety study of four proton pump inhibitors.

Bahtiri E, Islami H, Hoxha R, Qorraj-Bytyqi H, Rexhepi S, Hoti K, Thaçi K, Thaçi S, Karakulak Ç.

J Bone Miner Metab. 2016 Sep;34(5):571-9. doi: 10.1007/s00774-015-0699-6. Epub 2015 Jul 25.

PMID:
26209167
5.

Proton pump inhibitor use, hip fracture, and change in bone mineral density in postmenopausal women: results from the Women's Health Initiative.

Gray SL, LaCroix AZ, Larson J, Robbins J, Cauley JA, Manson JE, Chen Z.

Arch Intern Med. 2010 May 10;170(9):765-71. doi: 10.1001/archinternmed.2010.94.

6.

Vertebral fracture efficacy during risedronate therapy in patients using proton pump inhibitors.

Roux C, Goldstein JL, Zhou X, Klemes A, Lindsay R.

Osteoporos Int. 2012 Jan;23(1):277-84. doi: 10.1007/s00198-011-1574-5. Epub 2011 Mar 2.

PMID:
21365461
7.

Utilization of DXA Bone Mineral Densitometry in Ontario: An Evidence-Based Analysis.

Medical Advisory Secretariat.

Ont Health Technol Assess Ser. 2006;6(20):1-180. Epub 2006 Nov 1.

8.

Bone mineral density changes among women initiating proton pump inhibitors or H2 receptor antagonists: a SWAN cohort study.

Solomon DH, Diem SJ, Ruppert K, Lian YJ, Liu CC, Wohlfart A, Greendale GA, Finkelstein JS.

J Bone Miner Res. 2015 Feb;30(2):232-9. doi: 10.1002/jbmr.2344.

9.

Proton pump inhibitor use and the risk of osteoporosis and fracture in stroke patients: a population-based cohort study.

Lin SM, Yang SH, Liang CC, Huang HK.

Osteoporos Int. 2018 Jan;29(1):153-162. doi: 10.1007/s00198-017-4262-2. Epub 2017 Oct 14.

PMID:
29032384
10.

Relationship between bone mineral density changes and fracture risk reduction in patients treated with strontium ranelate.

Bruyere O, Roux C, Detilleux J, Slosman DO, Spector TD, Fardellone P, Brixen K, Devogelaer JP, Diaz-Curiel M, Albanese C, Kaufman JM, Pors-Nielsen S, Reginster JY.

J Clin Endocrinol Metab. 2007 Aug;92(8):3076-81. Epub 2007 Jun 12.

11.

Bone mineral density and vertebral fractures in men.

Legrand E, Chappard D, Pascaretti C, Duquenne M, Rondeau C, Simon Y, Rohmer V, Basle MF, Audran M.

Osteoporos Int. 1999;10(4):265-70.

PMID:
10692973
12.

The effect of proton pump inhibitors on fracture risk: report from the Canadian Multicenter Osteoporosis Study.

Fraser LA, Leslie WD, Targownik LE, Papaioannou A, Adachi JD; CaMos Research Group.

Osteoporos Int. 2013 Apr;24(4):1161-8. doi: 10.1007/s00198-012-2112-9. Epub 2012 Aug 14.

13.

Long-term effects of inhaled corticosteroids on bone mineral density in older women with asthma or COPD: a registry-based cohort study.

Chen W, Johnson KM, FitzGerald JM, Sadatsafavi M, Leslie WD.

Arch Osteoporos. 2018 Oct 29;13(1):116. doi: 10.1007/s11657-018-0537-2.

PMID:
30374631
14.

Nitrate use and changes in bone mineral density: the Canadian Multicentre Osteoporosis Study.

Jamal SA, Goltzman D, Hanley DA, Papaioannou A, Prior JC, Josse RG.

Osteoporos Int. 2009 May;20(5):737-44. doi: 10.1007/s00198-008-0727-7. Epub 2008 Sep 18. Retraction in: Osteoporos Int. 2016 Dec 1;:.

PMID:
18800179
15.

Loss of hip bone mineral density over time is associated with spine and hip fracture incidence in osteoporotic postmenopausal women.

Bruyere O, Varela AR, Adami S, Detilleux J, Rabenda V, Hiligsmann M, Reginster JY.

Eur J Epidemiol. 2009;24(11):707-12. doi: 10.1007/s10654-009-9381-4. Epub 2009 Aug 29.

PMID:
19728118
16.

Changes in bone mineral density after kidney transplantation: 2-year assessment of a French cohort.

Segaud N, Legroux I, Hazzan M, Noel C, Cortet B.

Osteoporos Int. 2018 May;29(5):1165-1175. doi: 10.1007/s00198-018-4383-2. Epub 2018 Mar 2.

PMID:
29500526
17.

Accelerated bone mineral loss following a hip fracture: a prospective longitudinal study.

Dirschl DR, Henderson RC, Oakley WC.

Bone. 1997 Jul;21(1):79-82.

PMID:
9213011
18.

Proton pump inhibitors, osteoporosis, and osteoporosis-related fractures.

Fournier MR, Targownik LE, Leslie WD.

Maturitas. 2009 Sep 20;64(1):9-13. doi: 10.1016/j.maturitas.2009.07.006. Epub 2009 Aug 11. Review.

PMID:
19674854
19.

Fracture risk and bone mineral density reduction associated with proton pump inhibitors.

Lau YT, Ahmed NN.

Pharmacotherapy. 2012 Jan;32(1):67-79. doi: 10.1002/PHAR.1007. Review.

PMID:
22392829
20.

Women's Mid-Life Night Sweats and 2-Year Bone Mineral Density Changes: A Prospective, Observational Population-Based Investigation from the Canadian Multicentre Osteoporosis Study (CaMos).

Wong EMM, Tomlinson G, Pinto MM, Berger C, Cheung AM, Prior JC.

Int J Environ Res Public Health. 2018 May 26;15(6). pii: E1079. doi: 10.3390/ijerph15061079.

Supplemental Content

Support Center